Prognostic Value of POST-Treatment Extent of Tumor (POSTTEXT) System in Patients with Hepatoblastoma
Cancer Research and Treatment · 15.10.2025 · 57 (4) · 1198-1206
DOI: 10.4143/crt.2024.600 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Research and Treatment, erschienen am 15.10.2025. Verfasst von Hana Jeong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Hepatoblastoma, Liver Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
PurposeThis study aimed to assess prognostic values of the POST-Treatment Extent of tumor (POSTTEXT) system and clinical factors after neoadjuvant chemotherapy in hepatoblastoma patients and evaluate benefits of post-treatment imaging and clinical factors concomitant with Children’s Hepatic Tumors International Collaboration–Hepatoblastoma Stratification (CHIC-HS) system.Materials and MethodsThis single-center retrospective study of hepatoblastoma cases (2006-2022) included pediatric patients receiving ≥ 4 cycles of neoadjuvant chemotherapy, with pre- and post-treatment imaging and complete medical records. Clinical data included age, sex, and serum α-fetoprotein (AFP) levels. Cox regression analyses identified predictors of event-free survival (EFS). Time-dependent receiver operating characteristic curves assessed the predictive power of combining the CHIC-HS risk stratification with post-treatment factors. Inter-reader agreement was analyzed using weighted kappa.ResultsAmong the 109 hepatoblastoma patients, 73 (mean age, 2.2±2.7 years) met the inclusion criteria. Prognostic factors for EFS included AFP levels after the fourth cycle of neoadjuvant chemotherapy (hazard ratio [HR], 1.233; 95% confidence interval [CI], 1.086 to 1.400; p=0.001), tumor size change ratio (HR, 0.654; 95% CI, 0.448 to 0.955; p=0.030), and POSTTEXT annotation factor M (HR, 5.209; 95% CI, 1.639 to 16.553; p=0.005). Incorporating AFP levels after the fourth cycle of neoadjuvant chemotherapy into the CHIC-HS improved predictive power (p=0.043). POSTTEXT system showed better inter-reader agreement than PRE-Treatment Extent of tumor (PRETEXT).ConclusionPredictors of EFS in hepatoblastoma include AFP levels after the fourth cycle of neoadjuvant chemotherapy, tumor size change ratio, and metastasis (POSTTEXT M). Combining AFP levels after the fourth cycle of neoadjuvant chemotherapy to the CHIC-HS improved the predictive ability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Pediatric Surgery, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea.
Zitieren
APA
Jeong, H., Yoon, H. M., Kim, P. H., Jung, A. Y., Cho, Y. A., Lee, J. S., Koh, K. N., & Namgoong, J. M. (2025). Prognostic Value of POST-Treatment Extent of Tumor (POSTTEXT) System in Patients with Hepatoblastoma. Cancer Research and Treatment, 57(4), 1198-1206. https://doi.org/10.4143/crt.2024.600
Vancouver
Jeong H, Yoon HM, Kim PH, Jung AY, Cho YA, Lee JS, et al. Prognostic Value of POST-Treatment Extent of Tumor (POSTTEXT) System in Patients with Hepatoblastoma. Cancer Research and Treatment. 2025;57(4):1198-1206. doi:10.4143/crt.2024.600
BibTeX
@article{Jeong2025,
author = {Jeong, Hana and Yoon, Hee Mang and Kim, Pyeong Hwa and Jung, Ah Young and Cho, Young Ah and Lee, Jin Seong and Koh, Kyung-Nam and Namgoong, Jung-Man},
title = {Prognostic Value of POST-Treatment Extent of Tumor (POSTTEXT) System in Patients with Hepatoblastoma},
journal = {Cancer Research and Treatment},
year = {2025},
volume = {57},
number = {4},
pages = {1198--1206},
doi = {10.4143/crt.2024.600}
}
EUVIMED